AMED 250117 75.00P (AMED250117P75000) Stock Options, News & Quotes - Moomoo

US OptionsDetailed Quotes

AMED250117P75000

Watchlist

0.85
+0.22+34.92%

15min DelayClose Dec 23 16:00 ET

0.85High0.85Low

Intraday

5D
Daily

News

Truist Financial Maintains Amedisys(AMED.US) With Hold Rating, Maintains Target Price $101
Moomoo NewsDec 23 07:33 ET · Ratings
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Neurocrine (NBIX) and Amedisys (AMED)
TipRanksDec 23 07:21 ET · Ratings
10 Health Care Stocks Whale Activity In Today's Session
BenzingaDec 11 12:35 ET
Amedisys Falls as Divestiture Buyer in Sale to UnitedHealth Has Legal Judgement Against It
Seeking AlphaDec 3 10:11 ET
Truist Financial Maintains Amedisys(AMED.US) With Hold Rating, Announces Target Price $101
Moomoo NewsNov 15 07:33 ET · Ratings
Truist Financial Keeps Their Hold Rating on Amedisys (AMED)
TipRanksNov 15 07:06 ET · Ratings

Comments

Michael_Lawrence

Sep 23, 2021 22:54

$Amedisys (AMED.US)$ divergency with good fundamental Also gap so it looks good and risk to rewards is acceptable

1

Jun 9, 2021 07:57

$Inhibikase Therapeutics (IKT.US)$
learn from
$Amedisys (AMED.US)$
$AMC Entertainment (AMC.US)$
$Fulcrum Therapeutics (FULC.US)$
JonesTrading analyst Soumit Roy initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $12.
$PharmaCyte Biotech (PMCB.US)$

2

Read more